Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Viridian Therapeutics Q2 EPS $(1.00) Beats $(1.02) Estimate, Sales $75.000K Beat $43.643K Estimate

Author: Benzinga Newsdesk | August 06, 2025 07:56am
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.02) by 2.44 percent. This is a 1.96 percent increase over losses of $(1.02) per share from the same period last year. The company reported quarterly sales of $75.000 thousand which beat the analyst consensus estimate of $43.643 thousand by 71.85 percent. This is a 4.17 percent increase over sales of $72.000 thousand the same period last year.

Posted In: VRDN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist